BioSig Technologies Appoints Wall Street Veteran, Brian McLaughlin To Lead Corporate Finance And Investor Relations
LOS ANGELES, CA / ACCESSWIRE / April 6, 2015 / BioSig Technologies (OTCQB:BSGM), a medical device company developing PURE EP(TM) a proprietary technology platform designed to improve the clinical outcomes of electrophysiology procedures, today announced the appointment of Brian McLaughlin as Vice President, Corporate Finance & Investor Relations. With over 19 years of financial experience, McLaughlin is a seasoned Wall Street veteran specializing in healthcare investments.
In this newly created role at BioSig Technologies, McLaughlin will be responsible for leading the acquisition of strategic capital and to further develop investor relationships. During his tenure in the money management industry, McLaughlin held senior roles with some of the leading U.S. hedge funds. In that capacity, he built an extensive network of relationships that will bring tremendous value to BioSig. He will report to Kenneth Londoner, Co-founder and Executive Chairman of BioSig Technologies.
Kenneth Londoner, Co-founder and Executive Chairman stated, "Brian is at the cutting edge of leading money management professionals transitioning from top hedge funds to emerging and entrepreneurial growth companies. His knowledge of finance, capital markets, and understanding what today's top healthcare investors are looking for in young medical companies, makes him an invaluable addition to our strong team. Brian had top roles in very successful healthcare investment firms and will allow BioSig to build out an internal investor relations effort."
McLaughlin held senior executive positions in the hedge fund industry for over 13 years at Sigma Capital Mgt., SAC Capital Mgt., and the investment bank, JP Morgan & Co. At Ridgeback Capital, McLaughlin was president and chief operating officer managing over a billion dollars, specifically investing in the healthcare industry.
Brian McLaughlin stated, "I could not be more thrilled to join this dynamic team. I have considered making this industry change for some time. BioSig's founder, Ken Londoner, made the same hedge fund to emerging growth company change thirteen years ago; and, working together, we intend to create an investor relations capability that is unique in scale and performance."
McLaughlin received a Bachelor of Arts degree in Communications from Marist College in 1996.
About BioSig Technologies
BioSig Technologies is a medical device company that has developed a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (EP) marketplace(1) (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP System.
PURE EP System is a next-generation surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing guidance in identifying ablation targets - areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1) - making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig intends to seek FDA 510(k) approval for the PURE EP System. The Company has already achieved proof of concept validation through UCLA EP & Animal Labs, and is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.
This release includes forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, regulatory approvals, competition and marketplace demand. More information, and BioSig risk factors, are set forth in its filings with the SEC. BioSig assumes no obligation to publicly update or revise its forward-looking statements.
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.